• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period

    1/13/25 9:00:00 AM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email
    • Robust plan benefits powered member growth, mainly driven by switchers from other plans
    • Company will focus on balancing profitability with strategic investments in growth and technology to take advantage of strong market opportunity
    • ~95% of Clover's January 1, 2025 membership is in its flagship 4 Star PPO plan

    WILMINGTON, Del., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced a 27% year-over-year growth of its Medicare Advantage (MA) membership during the most recent Annual Election Period (AEP). The Company enters 2025 with over 100,000 members, approximately 95% of whom are enrolled in Clover's flagship 4-Star PPO plan.

    "Driven by robust plan benefits and our 4 Star rating, we've delivered exceptional member growth, and I feel honored to bring so many new people into our unique model of care," said Andrew Toy, CEO of Clover Health. "We invest deeply in using technology to improve clinical outcomes through the earlier identification, management and treatment of chronic disease, a clear differentiator from our peers. Looking forward, we will take advantage of the strong market opportunity in front of us, by making strategic investments in growth as well as continuing to widen our AI-powered technology moat."

    Clover's 4-Star rating PPO plan reflects the Company's deep investment in care quality, with top performance across key HEDIS measures—an industry standard for healthcare quality. This achievement also positions Clover for an anticipated 5% benchmark increase in payment year 2026 (PY26), strengthening the company's ability to reinvest in improving benefits and further accelerating membership growth.

    Jamie Reynoso, CEO of Medicare Advantage at Clover Health, added: "Our foundational investments over the last few years—ranging from enhanced care management to operational efficiencies—are paying off. Keeping a keen focus on improving the health of our members, by being an active participant in their care management, Clover is in an incredibly strong position to continue this above-market growth trajectory while of course maintaining profitability. Our strong membership growth, coupled with the expected 2026 tailwinds of our 4-Star rating and increasing impact of our integrated care model, positions Clover for long-term Medicare Advantage success. We're excited to keep pushing forward."

    About Clover Health:

    Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements regarding future events and Clover Health's future results of operations, financial condition, market size and opportunity, business strategy and plans, and the factors affecting our performance and our objectives for future operations. Forward-looking statements are not guarantees of future performance and you are cautioned not to place undue reliance on such statements. In some cases, you can identify forward looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "can," "could," "should," "would," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "outlook," "forecast," "guidance," "objective," "plan," "seek," "grow," "if," "continue" or the negative of these words or other similar terms or expressions that concern Clover Health's expectations, strategy, priorities, plans or intentions. Forward-looking statements in this press release include, but are not limited to, the following: statements regarding the Company's Annual Election Period results and 2025 market growth and their anticipated effects on the Company's financial performance, the anticipated number of Clover Health Insurance members, Adjusted EBITDA profitability, and the Company's Star Ratings and its affect on future membership growth and profitability, as well as the statements contained in the quotations of our executive officers and other expectations as to future performance, operations and results. Forward-looking statements regarding our Adjusted EBITDA profitability are based on our current targets which are preliminary and are derived from our 2025 financial outlook. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by forward-looking statements in this press release. Forward-looking statements involve a number of judgments, risks and uncertainties, including, without limitation, risks related to: our expectations regarding results of operations, financial condition, and cash flows; our expectations regarding the development and management of our Insurance business; our ability to successfully enter new service markets and manage our operations; anticipated trends and challenges in our business and in the markets in which we operate; our ability to effectively manage our beneficiary base and provider network; our ability to maintain and increase adoption and use of Clover Assistant, including the expansion of Clover Assistant for external payors and providers under the brand name Counterpart Assistant; the anticipated benefits associated with the use of Clover Assistant, including our ability to utilize the platform to manage our medical care ratios; our ability to maintain or improve our Star Ratings or otherwise continue to improve the financial performance of our business; our ability to develop new features and functionality that meet market needs and achieve market acceptance; our ability to retain and hire necessary employees and staff our operations appropriately; the timing and amount of certain investments in growth; the outcome of any known and unknown litigation and regulatory proceedings; any current, pending, or future legislation, regulations or policies that could have a negative effect on our revenue and businesses, including rules, regulations, and policies relating to healthcare and Medicare; our ability to maintain, protect, and enhance our intellectual property; general economic conditions and uncertainty; persistent high inflation and interest rates; and geopolitical uncertainty and instability. Additional information concerning these and other risk factors is contained under Item 1A. "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 14, 2024, as such risks may be updated in our subsequent filings with the SEC. The forward-looking statements included in this press release are made as of the date hereof. Except as required by law, Clover Health undertakes no obligation to update any of these forward-looking statements after the date of this press release or to conform these statements to actual results or revised expectations.

    Press Contact:

    Andrew Still-Baxter

    [email protected]

    Investor Relations Contact:

    Ryan Schmidt

    [email protected]



    Primary Logo

    Get the next $CLOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Oldakowski Joseph Frank

    3 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/9/26 7:46:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form 3 filed by new insider Thornton Joseph Clay

    3/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/9/26 6:12:51 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Thornton Joseph Clay

    3 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/9/26 6:03:13 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    SEC Filings

    View All

    Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    4/1/26 8:32:45 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Clover Health Investments Corp.

    SCHEDULE 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    3/26/26 5:13:27 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 144 filed by Clover Health Investments Corp.

    144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    3/18/26 4:32:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership

    WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, in partnership with HealthEx, today announced a new collaboration that enables Clover Medicare Advantage (MA) members to securely access and share clinical records and claims data, further advancing patients rights to access and share their own health data, which is central to federal interoperability efforts. Through HealthEx, Clover members can choose to connect their health information to tools like Claude so they can better understand and

    4/7/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Clover Health with a new price target

    Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

    12/17/24 8:33:41 AM ET
    $CLOV
    Medical Specialities
    Health Care

    UBS initiated coverage on Clover Health with a new price target

    UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

    10/7/24 7:45:42 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SVB Leerink reiterated coverage on Clover Health Investments with a new price target

    SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

    2/25/22 5:03:33 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/13/24 4:06:53 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

    WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial

    9/18/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

    WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations. As Counterpart scales to meet growing demand from payors and providers nationwide, Bruner will lead several critical functions including customer implementations, provider network engagement, clinician onboarding and training, and longitudinal account support. Her work will be foundational, ensuring operational readiness and delivery consisten

    7/29/25 4:30:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Financials

    Live finance-specific insights

    View All

    Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026

    WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. First Quarter 2026 Conference Webcast Details: What: Clover Health's First Quarter 2026 Earnings Conference CallWhen: Wednesday, May 6, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https://clover-health-1q26-earnings-call.ope

    4/8/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance

    Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu

    2/26/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Clover Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter. Fourth Quarter and Full Year 2025 Conference Webcast Details: What: Clover Health's Fourth Quarter and Full Year 2025 Earnings Conference CallWhen: Thursday, February 26, 2026, at 5:00 p.m. Eastern TimeWebcast: To access the webcast, you may register at https

    1/29/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/12/24 2:31:31 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    11/4/24 11:25:56 AM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

    SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

    7/7/23 4:35:52 PM ET
    $CLOV
    Medical Specialities
    Health Care